Could A New Narrative Be Forming? Protara & LMs
Protara Therapeutics (Nasdaq: TARA) is expected to report interim data from its ongoing Phase 2/2b study, titled STARBORN, with TARA-002 in lymphatic malformations (LMs)…
Coverage
Blog
Latest research notes and coverage from the editorial archive.
Ventyx: Celebrate a CRP Hit & Dismiss an Obesity Miss
Last week, Ventyx Biosciences (Nasdaq: VTYX) announced the results from a Phase 2a study with its oral CNS-penetrant NLRP3 inhibitor, VTX3232, in obese patients…
More Patience Required: Delcath
This past weekend, Delcath Systems (Nasdaq: DCTH) announced clinical data from the CHOPIN study that are highly encouraging for Hepzato’s medium- to long-term growth…
Ovid’s Data Parade & Eupraxia’s Expansion
Last week, Ovid Therapeutics (Nasdaq: OVID) announced data from its Phase 1b pharmacodynamic (PD) study with OV329, its next-generation GABA-AT inhibitor, along with a…
With Biotech Risk-On, Let’s Revisit Gain & Satellos
With risk coming back on for biotech, we decided to revisit a couple of smaller names from our past that have provocative technology and…
Proof of Concept, FDA Alignment, and Durability: Ovid, Rezolute & Eupraxia
As September begins, one of the remaining key catalysts in our universe for Q3 is Ovid Therapeutics’ (Nasdaq: OVID) Phase 1b results for its…
Patience Required: Delcath & RenovoRx
Patience Required A few weeks ago, Delcath Systems (Nasdaq: DCTH) reported another strong quarter, but the stock continued to fight the headwinds caused by…
Ovid and Xenon: Too Early to Draw Parallels?
Our Approach / Our Blindspot We don’t put buy or sell ratings on the companies we discuss. We don’t volunteer price targets. We share…
Degrees of Good: Data From Nektar, Compass, and Ventyx
Over the past week, it felt like BioX (BioTwitter) was back to its old, vibrant self, and we have Nektar Therapeutics (Nasdaq: NKTR) to…
Expectations For Impending June Data From Nektar, Ventyx & Compass/Cybin
Among the companies in our universe, several upcoming data releases are expected in June. Nektar Therapeutics (Nasdaq: NKTR) will report Phase 2b data for…